Acute phosphate nephropathy - An emerging issue

American Journal of Gastroenterology

Volumn 102, Issue 9, 2007, Pages 1844-1847

  Sica, Domenic A ^a   Carl, Dan ^b   Zfass, Alvin M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OSMOPREP; SODIUM DIHYDROGEN PHOSPHATE; UNCLASSIFIED DRUG; VISICOL;

ACUTE PHOSPHATE NEPHROPATHY; COLONOSCOPY; DEHYDRATION; ELECTROLYTE DISTURBANCE; FLUID INTAKE; GASTROENTEROLOGY; GLOMERULUS FILTRATION RATE; HUMAN; HYPOCALCEMIA; INTESTINE MOTILITY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CIRRHOSIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CATHARTICS; COLONOSCOPY; HUMANS; KIDNEY FAILURE, ACUTE; PHOSPHATES; RISK FACTORS;

EID: 34548136565     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01047.x     Document Type: Review

References (25)

1. Kastenberg D, Chasen R, Choudhary C, et al. Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: Two identically designed, randomized, controlled, parallel group, multicenter phase III trials. Gastrointest Endosc 2001 54 : 705 13.
2. Khashab M, Rex DK. Efficacy and tolerability of a new formulation of sodium phosphate tablets (INKP-101), and a reduced sodium phosphate dose, in colon cleansing: A single-center open-label pilot trial. Aliment Pharmacol Ther 2005 21 : 465 8.
3. Cohen SM, Wexner SD, Binderow SR, et al. Prospective, randomized, endoscopic-blinded trial comparing precolonoscopy bowel cleansing methods. Dis Colon Rectum 1994 37 : 689 96.
4. Faigel DO, Eisen GM, Baron TH, et al. Preparation of patients for GI endoscopy. Am Soc Gastrointest Endosc 2003 57 : 446 50.
5. Product Information: OSMOPREP(TM) oral tablets, sodium phosphate monbasic monohydrate and sodium phosphate dibasic anhydrous oral tablets. Salix Pharmaceuticals, Inc., Morrisville, NC, 2006.
6. Product Information: VISICOL(R) oral tablets, sodium phosphate monobasic monohydrate, dibasic anhydrous oral tablets. Salix Pharmaceuticals, Inc, Morrisville, NC, 2006.
7. Schiller LR. Clinical pharmacology and use of laxatives and lavage solutions. J Clin Gastroenterol 1999 28 : 11 8.
8. Curran MP, Plosker GL. Oral sodium phosphate solution: A review of its use as a colorectal cleanser. Drugs 2004 64 : 1697 714.
9. Rex DK, Schwartz H, Goldstein M, et al. Safety and colon-cleansing efficacy of a new residue-free formulation of sodium phosphate tablets. Am J Gastroenterol 2006 101 : 2594 604.
10. Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med 2003 163 : 803 8.
11. Gumurdulu Y, Serin E, Ozer B, et al. Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation. J Gastroenterol Hepatol 2004 19 : 68 72.
12. Markowitz GS, Whelan J, D'Agati VD. Renal failure following bowel cleansing with a sodium phosphate purgative. Nephrol Dial Transplant 2005 20 : 850 1.
13. Markowitz GS, Stokes MB, Radhakrishnan J, et al. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: An underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005 16 : 3389 96.
14. Markowitz GS, Nasr SH, Klein P, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004 35 : 675 84.
15. Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med 2003 349 : 1006 7.
16. Gonlusen G, Akgun H, Ertan A, et al. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing. Arch Intern Med 2006 130 : 101 6.
17. http://www.phosphosoda.com(professionals/pdf/v5-revisedDearDrLetter.pdf. Accessed October 27, 2006.
18. Oral sodium phosphate solution for bowel preparation: literature review and recommendations of an industry-sponsored advisory panel regarding safe and effective use. Available at : http://www.phosphosoda.com/professionals. Accessed October 22, 2006.
19. U.S. Food and Drug Administration. Acute phosphate nephropathy and renal failure associated with the use of oral sodium phosphate bowel cleansing products. U.S. Food and Drug Administration, Rockville, MD, 2006. Available at : http://www.fda.gov/cder/drug/infopage/osp_solution/science_background.pdf. Accessed October 22, 2006.
20. U.S. Food and Drug Administration. Oral sodium phosphate products for bowel cleansing. U.S. Food and Drug Administration, Rockville, MD, 2006. Available at : http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf. Accessed August 27, 2006.
21. A consensus document on bowel preparation before colonoscopy : Prepared by a Task Force from the Society for Colorectal Surgery, the American Society for Gastrointestinal Endoscopy, and the Society of American Gastrointestinal and Endoscopic Surgeons. Gastrointest Endosc 2006 63 : 894 909.
22. http://www.phosphosoda.com/professionals/pdf/PDR_PHOSPHOSODAORAL.pdf. Accessed October 22, 2006.
23. Rostom A, Jolicoeur E, Dube C, et al. A randomized prospective trial comparing different regimens of oral sodium phosphate and polyethylene glycol-based lavage solution in the preparation of patients for colonoscopy. Gastrointest Endosc 2006 64 : 544 52.
24. http://www.fda.gov/cder/foi/appletter/2006/021097s010ltr.pdf. Accessed October 22, 2006.
25. Tan JJ, Tjandra JJ. Which is the optimal bowel preparation for colonoscopy - a meta-analysis. Colorectal Dis 2006 8 : 247 58.